00:00 / 00:00
DISEASE-MODIFYING THERAPY for MULTIPLE SCLEROSIS | ||
DRUG NAME | dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), fingolimod (Gilenya), glatiramer (Copaxone, Glatopa) interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia) | rituximab (Riabni, Rituxan), natalizumab (Tysabri), ocrelizumab (Ocrevus), alemtuzumab (Campath, Lemtrada) |
CLASS | Immunomodulators | Monoclonal antibodies |
MECHANISM of ACTION | Blunt inflammatory process → lessen the severity and frequency of relapses → slow disease progression, mitigate symptoms, and improve client’s quality of life | |
INDICATIONS |
| |
ROUTE(S) of ADMIN |
|
|
SIDE EFFECTS |
|
|
CONTRAINDICATIONS & CAUTIONS |
|
NURSING CONSIDERATIONS for DISEASE-MODIFYING THERAPY for MULTIPLE SCLEROSIS | ||
ASSESSMENT & MONITORING | Assessment & monitoring: natalizumab Assessment
Administration / Intervention
Monitoring
| |
CLIENT EDUCATION |
|
Multiple sclerosis, or MS for short, is a chronic and progressive demyelinating disease of the central nervous system. Myelin is the protective sheath that surrounds the axons of neurons, allowing them to quickly send electrical impulses. In MS, demyelination happens when the immune system inappropriately attacks and destroys the myelin. As a result communication between neurons breaks down, ultimately leading to various sensory, motor, and cognitive problems. Although there’s no cure for MS, disease-modifying therapy can be used to help slow the disease progression, as well as mitigate some of the symptoms, and ultimately improve the client’s quality of life.
Now, disease-modifying therapy for MS includes monoclonal antibodies and immunomodulators. The most commonly used monoclonal antibodies for MS include rituximab, natalizumab, ocrelizumab, and alemtuzumab, which are administered intravenously. On the other hand, immunomodulators for MS include dimethyl fumarate, teriflunomide, and fingolimod, which are administered orally, as well as glatiramer and recombinant human interferon beta-1a and interferon beta-1b, which can be injected intramuscularly or subcutaneously.
Once administered, these medications blunt the inflammatory process, which ultimately helps reduce the severity and frequency of relapses or exacerbation of multiple sclerosis.
Unfortunately, these medications can cause side effects like bone marrow suppression, which can result in anemia, thrombocytopenia, leukopenia, and an increased risk for infections. In fact, for alemtuzumab, that’s a boxed warning, with an increased risk of developing fatal infections, autoimmune effects, and malignancy.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.